ReviewDrugs2005
Autoimmune bullous diseases: ocular manifestations and management.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 51 citations in OpenAlex.
- Conjunctival biopsy findings associated with fibrosis and sequelae in ocular Mucous membrane pemphigoid.International ophthalmology · 2026Article
- Ocular involvement in oral vesiculobullous diseases: A review on reported cases in the literature.The Saudi dental journal · 2024Review
- Clinical Approach to Ocular Cicatricial Pemphigoid.Turkish journal of ophthalmology · 2023Article
- Ocular surface disorders affect quality of life in patients with autoimmune blistering skin diseases: a cross-sectional study.BMC ophthalmology · 2022Article
- Article
- A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.Orphanet journal of rare diseases · 2018Review
- Recurrent corneal melting in the paraneoplastic pemphigus associated with Castleman's disease.BMC ophthalmology · 2016Article
- Cicatricial changes in ocular pemphigus.Eye (London, England) · 2014Article
- Paraneoplastic pemphigus: a paraneoplastic autoimmune multiorgan syndrome or autoimmune multiorganopathy?Case reports in dermatological medicine · 2012Article
- Ocular involvement and blindness secondary to linear IgA dermatosis.Journal of ophthalmology · 2010Article
- [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2008Review
- Response of ocular pemphigus vulgaris to therapy. Case report and review of literature.Journal of dermatological case reports · 2008Article
- Ocular Manifestations and Management of Autoimmune Bullous Diseases.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmune-induced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including methotrexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.